A Phase 1 interventional study of AZD7798 and [11C]AZ14132516 in Crohn's Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.
Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 1, and was the 10th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3
First in 2006; this study’s year is marked. 1 started in 2023.
This study's enrollment of 13 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 48 across the 13 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Crohn Disease by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the changes in small bowel uptake of radioligand [11\^C]AZ14132516 after intravenous (IV) administration of single and repeat doses of AZD7798 in healthy participants and participants with Crohn's disease.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HEALTHY PARTICIPANTS:
Participant must be ≥ 20 to 65 years of age inclusive, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory parameters, and cardiac monitoring before first administration of product.
Weight
use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Male participants:
(i) Women of non-child bearing potential are defined as meeting one of the following criteria at screening:
(ii) Woman of childbearing potential (WOCBP ie, not meeting criteria above) must have a negative pregnancy test at screening and before PET examination.
(iii) If sexually active with a non-sterilized male partner, WOCBP must use at least one highly effective method of birth control during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer.
(iv) It is strongly recommended that non-sterilized male partners of WOCBP participants use a male condom plus spermicide during the study period.
(v) WOCBP participants must not breastfeed and must not donate or retrieve ova for their own use during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer (c) Highly effective methods of birth control (i) Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:
PARTICIPANTS WITH CROHN'S DISEASE
<!-- -->
Exclusion Criteria:
HEALTHY PARTICIPANTS:
History of cancer with the following exceptions
(a) Solid with curative therapy completed at least 5 years prior to screening (b) Basal cell carcinoma or localized squamous cell carcinoma of the skin or in-situ carcinoma of the cervix, provided that curative therapy was completed at least 12 months prior to screening
Abnormal vital signs, after 10 minutes of supine rest as judged by the investigator. As a guide, any readings outside the following should be considered in the evaluation:
(a) systolic blood pressure (BP) ≥ 150 mmHg (b) diastolic BP ≥ 90 mmHg (c) heart rate ≤ 35 beats per minute (bpm) or ≥ 100 bpm The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the Principal Investigator (PI).
Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of changes. This may include participants with any of the following:
Positive , , or (HIV) serology as defined by:
(a) Hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibodies (anti-HBc Ab) positivity (b) Anti-hepatitis C virus antibodies (anti-HCV Ab) positivity (c) Anti-HIV antibodies (Ab) positivity Prior/Concomitant Therapy
PARTICIPANTS WITH CROHN'S DISEASE
Abnormal vital signs, after 10 minutes of supine rest as judged by the investigator. As a guide, any readings outside the following should be considered in the evaluation:
Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This may include participants with any of the following:
The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the PI.
Positive hepatitis B, hepatitis C or HIV serology as defined by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.
Drug: AZD7798 · Drug: [11C]AZ14132516
Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 56.
Drug: AZD7798 · Drug: [11C]AZ14132516
Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 2 and Day 42.
Drug: AZD7798 · Drug: [11C]AZ14132516
Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.
Drug: AZD7798 · Drug: [11C]AZ14132516
Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.
Drug: AZD7798 · Drug: [11C]AZ14132516
Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by IV infusion of AZD7798 Dose Level 1 on Day 1 (Dose 1) and Day 15 (Dose 2). Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 28.
Drug: AZD7798 · Drug: [11C]AZ14132516
Participants will receive IV infusion of AZD7798 as stated in arm description.
Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.
Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (Positron Emission Tomography [PET]1 Visit) to PET2 Visit
Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET2 visit is reported.
Time frame: PET1 visit (baseline; Day -7 to Day -1) and PET2 visit (Day 14 for all panels except Day 2 for Panel 3)
Percentage Change in Small Bowel Kp From Baseline (PET1 Visit) to PET3 Visit
Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET3 visit is reported.
Time frame: PET1 visit (baseline; Day -7 to Day -1) and PET3 visit (Day 42 for all panels except Days 56 and 28 for Panels 2 and 6, respectively)
Percentage Change From Baseline in Circulating C-C Chemokine Receptor Type 9 Positive (CCR9+) Memory T Cells in Panels 1 to 5
CCR9+ memory T cells in blood were evaluated by flow cytometry. Percentage change from baseline in circulating CCR9+ memory T cells is reported.
Time frame: Panels 1-5: Pre-dose (baseline) and 6 and 24 hours post-dose on Day 1, additionally; Panels 1, 4, and 5: Days 14 and 42; Panel 2: Day 14; Panel 3: Days 2 and 42
Percentage Change From Baseline in Circulating CCR9+ Memory T Cells in Panel 6
CCR9+ memory T cells in blood were evaluated by flow cytometry. Percentage change from baseline in circulating CCR9+ memory T cells is reported.
Time frame: Pre-dose of Dose 1 (baseline), and 6 and 24 hours post-dose 1 on Day 1; pre-dose and 24 hours post-dose 2 on Day 15; and on Day 28
Change From Baseline in C-C Chemokine Receptor Type 9 (CCR9) Receptor Occupancy as Free CCR9 on Total CCR9 Memory T cells in Blood in Panels 1 to 5
CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood was evaluated by flow cytometry. Change from baseline in CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood is reported.
Time frame: Panels 1-5: Pre-dose (baseline) and 6 and 24 hours post-dose on Day 1, additionally; Panels 1, 4, and 5: Days 14 and 42; Panel 2: Day 14; Panel 3: Days 2 and 42
Change From Baseline in CCR9 Receptor Occupancy as Free CCR9 on Total CCR9 Memory T cells in Blood in Panel 6
CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood was evaluated by flow cytometry. Change from baseline in CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood is reported.
Time frame: Pre-dose of Dose 1 (baseline), and 6 and 24 hours post-dose 1 on Day 1; pre-dose and 24 hours post-dose 2 on Day 15; and on Day 28
Serum Concentrations of AZD7798 in Panels 1 to 5
Serum concentrations of AZD7798 collected over time are reported.
Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2
Serum Concentrations of AZD7798 in Panel 6
Serum concentration of AZD7798 collected over time are reported.
Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29
Maximum Serum Concentration (Cmax) of AZD7798 in Panels 1 to 5
The Cmax of AZD7798 is reported.
Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2
Cmax of AZD7798 in Panel 6
The Cmax of AZD7798 is reported.
Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Measured Concentration (AUClast) of AZD7798 in Panels 1 to 5
The AUClast of AZD7798 is reported.
Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2
AUClast of AZD7798 in Panel 6
The AUClast of AZD7798 is reported.
Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29
Time to Maximum Serum Concentration (Tmax) of AZD7798 in Panels 1 to 5
The Tmax of AZD7798 is reported.
Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2
Tmax of AZD7798 in Panel 6
The Tmax of AZD7798 is reported.
Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29
Last Measured Serum Concentration (Tlast) of AZD7798 in Panels 1 to 5
The Tlast of AZD7798 is reported.
Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2
Tlast of AZD779 in Panel 6
The Tlast of AZD7798 is reported.
Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, pulse rate, and oxygen saturation).
Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of clinical chemistry, hematology, coagulation, urinalysis, and drug abuse (healthy participants only).
Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Oct 2024, 12 months.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD7798